Pemigatinib · Pemazyre

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Cholangiocarcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signalSingle-arm, accepted for approval (FDA label)

Also in development:Non-Small Cell Lung Cancer · Phase 2

Also approved (4)
US
  • Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.
Product first approved 2020Outside this platform's coverageFDA label
CN
  • Adults with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement, previously treated
Product first approved 2022medthority.com
EU
  • Conditional marketing authorisation: locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after at least one prior systemic therapy
Product first approved 2021EMA
JP
  • Unresectable biliary tract cancer with FGFR2 fusion gene, worsening after chemotherapy
Product first approved 2021onclive.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Cholangiocarcinoma
Phase 2 (40)
Cholangiocarcinoma
NCT07862998 · Incyte Corporation
2026-12-15 – 2031-03-27 · Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma
What this study did
NCT07786766 · Haitao Zhao, MD
2026-08-20 – 2028-12-31 · Biliary Tract Cancer (BTC)
What this study did
NCT06530823 · Eastern Hepatobiliary Surgery Hospital
2024-08-01 – 2028-08-01 · Biliary Tract Carcinoma, Cholangiocarcinoma
What this study did
NCT06728410 · Mehmet Akce
2026-01-27 – 2028-07 · Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation
What this study did
NCT07780838 · Ohio State University Comprehensive Cancer Center
2026-11-01 – 2027-12-31 · Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Gallbladder Carcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Ampulla of Vater Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Ampulla of Vater Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Ampulla of Vater Carcinoma, Unresectable Biliary Tract Carcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT05565794 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2022-11-11 – 2025-03-27 · Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement, FGFR2 Gene Translocation
What this study did
NCT05913661 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-07 – 2024-11 · Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms, PD-1 Inhibitor, First-line Treatment
What this study did
NCT04256980 · Innovent Biologics (Suzhou) Co. Ltd.
2020-03-03 – 2023-08-31 · Cholangiocarcinoma
What this study did
Non-Small Cell Lung Cancer
NCT05004974 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2022-04-26 – 2025-09 · Advanced Non Small Cell Lung Cancer
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
Other / comorbidity
NCT05159245 · Helsinki University Central Hospital
2021-12-10 – 2032-11-25 · Advanced Cancer, Solid Tumor, Haematological Malignancy
What this study did
NCT07434843 · Dana-Farber Cancer Institute
2026-05-19 – 2029-04-01 · SDH Gene Mutation, Gastrointestinal Stromal Tumor
What this study did
NCT06906562 · Sameek Roychowdhury
2025-08-26 – 2028-12-31 · Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT06389799 · Lund University Hospital
2024-06-20 – 2028-12-31 · Dedifferentiated Liposarcoma
What this study did
NCT06653777 · UNICANCER
2025-03-27 – 2028-06-30 · Solid Tumor, Miscellaneous
What this study did
NCT02925234 · The Netherlands Cancer Institute
2016-08 – 2027-12 · Cancer, Tumors, Neoplasm, Neoplasia
What this study did
NCT03914794 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020-10-02 – 2027-07-01 · Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
What this study did
NCT06300528 · University of Utah
2025-10-03 – 2027-03 · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
What this study did
NCT06551896 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-08-15 – 2026-12-31 · Urothelial Carcinoma, Breast Neoplasms, Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Other Carcinoma
What this study did
NCT05651672 · Tianjin Medical University Cancer Institute and Hospital
2022-12-02 – 2026-12 · Gastrointestinal Cancer
What this study did
NCT04096417 · Academic and Community Cancer Research United
2020-08-31 – 2025-12-01 · FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR2 Gene Translocation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, FGFR3 Gene Translocation, Metastatic Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
What this study did
NCT05560334 · Tianjin Medical University Cancer Institute and Hospital
2022-09-08 – 2025-09-08 · Breast Cancer
What this study did
NCT05216120 · HonorHealth Research Institute
2022-06-14 – 2025-08-31 · Pancreas Cancer
What this study did
NCT06022289 · Tianjin Medical University Second Hospital
2023-05-01 – 2025-05-31 · Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification, FGF Receptor Gene Family Rearrangement, FGF Receptor Gene Translocation
What this study did
NCT05997459 · Sun Yat-sen University
2023-08-25 – 2025-03-30 · Locally Advanced Unresectable Gastric Cancer
What this study did
NCT03011372 · Incyte Corporation
2017-04-25 – 2024-10-30 · MPN (Myeloproliferative Neoplasms)
What this study did
NCT05202236 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2021-10-13 – 2024-10-13 · Gastric and Colorectal Cancer
What this study did
NCT04949191 · Incyte Corporation
2021-07-08 – 2024-04-11 · Advanced Malignancies
What this study did
NCT04294277 · European Association of Urology Research Foundation
2020-07-13 – 2022-11-15 · Urothelial Cancer
What this study did
NCT02872714 · Incyte Corporation
2017-01-12 – 2022-02-01 · UC (Urothelial Cancer)
What this study did
NCT04003610 · Incyte Corporation
2020-05-14 – 2021-04-18 · Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
What this study did
NCT04003623 · Incyte Corporation
2019-10-31 – 2020-06-12 · Advanced or Metastatic Solid Tumors, FGFR Mutations, FGFR Translocations
What this study did
Phase 1/2 (3)
Cholangiocarcinoma
NCT06439485 · M.D. Anderson Cancer Center
2024-11-19 – 2030-02-22 · Advanced Cholangiocarcinoma, FGFR2 Fusion
What this study did
NCT02393248 · Incyte Corporation
2015-02-27 – 2021-12-17 · Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN
What this study did
Other / comorbidity
NCT05529667 · Yonsei University
2019-05-27 – 2023-08-30 · Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
What this study did
Phase 1 (5)
Cholangiocarcinoma
NCT06302621 · Massachusetts General Hospital
2024-04-17 – 2027-12-01 · Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
What this study did
NCT04088188 · Academic and Community Cancer Research United
2021-01-25 – 2023-12-01 · Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma
What this study did
Other / comorbidity
NCT04258527 · Innovent Biologics (Suzhou) Co. Ltd.
2020-03-26 – 2021-03-08 · Solid Tumor
What this study did
NCT03235570 · Incyte Corporation
2017-08-01 – 2020-03-04 · Solid Tumors
What this study did
Early phase / not applicable (1)
Non-Small Cell Lung Cancer
NCT05210946 · The First Affiliated Hospital of Soochow University
2021-12-06 – 2024-12-06 · Non-Small Cell Lung Cancer
What this study did

Competitive landscape

This drug's own stage for Cholangiocarcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pemigatinib (Pemazyre): this drugApprovedSmall moleculeFGFR1/2/3Weak signalNo reviewed efficacy summary in this indication
Futibatinib (Lytgobi)ApprovedSmall moleculeFGFR (FGFR1/2/3/4)Weak signalNo reviewed efficacy summary in this indication
Lirafugratinib (Lyrfigtu)ApprovedSmall moleculeFGFR2not yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
TinengotinibPhase 3Small moleculeAurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition)Weak signalFeatured results are safety only in this race
ToripalimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pemazyre (Pemigatinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT04659616 · CT.gov ↗
What to watch
Phase 2Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2026-12-31 · NCT06906562 · CT.gov ↗
What to watch
2027 (7)
June 2027 (1)
Phase 2Solid Tumor, MiscellaneousRecruiting
Est. primary completion 2027-06-30 · NCT06653777 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2CholangiocarcinomaRecruiting
Est. primary completion 2027-07 · NCT06728410 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
December 2027 (4)
Phase 1CholangiocarcinomaRecruiting
Est. primary completion 2027-12-01 · NCT06302621 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07786766 · CT.gov ↗
What to watch
Phase 2Dedifferentiated LiposarcomaRecruiting
Est. primary completion 2027-12-31 · NCT06389799 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07780838 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Phase 1/2CholangiocarcinomaRecruiting
Est. primary completion 2028-02-22 · NCT06439485 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2SDH Gene Mutation, Gastrointestinal Stromal TumorRecruiting
Est. primary completion 2028-10-01 · NCT07434843 · CT.gov ↗
What to watch
2031 (2)
February 2031 (1)
Phase 2CholangiocarcinomaNot yet recruiting
Est. primary completion 2031-02-25 · NCT07862998 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2031-11-25 · NCT05159245 · CT.gov ↗
What to watch

See the full readout calendar ↗